(Reuters) – Verona Pharma’s therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday.
The U.S. health regulator’s assent on Wednesday for the therapy, branded as Ohtuvayre, provides a new inhaled non-steroidal treatment for chronic obstructive pulmonary disease.
(Reporting by Pratik Jain in Bengaluru; Editing by Shounak Dasgupta)
